FindMyKOL
Clinical trialNCT07835789Not, yet, recruitingPhase 2Interventional

Testing Repeat Radiation Therapy for Recurrent Non-small Cell Lung Cancer

NCT07835789 is a phase 2 interventional trial sponsored by NRG Oncology. As of 21 Nov 2026, it is not yet recruiting. It studies Systemic Chemotherapy in Locally Recurrent Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8 and 1 more condition. The registry lists an enrollment of 138 participants. The registry lists a start date of 18 Dec 2026 and a primary completion date of 30 Sept 2029. One of its registered investigators has a FindMyKOL profile.

SponsorNRG Oncology →Enrollment138Locally Recurrent Lung Non-Small Cell CarcinomaStage II Lung Cancer AJCC v8Stage III Lung Cancer AJCC v8
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT07835789
FieldValue
Registry IDNCT07835789
StatusNot yet recruiting
PhasePhase 2
Study typeInterventional trial
Lead sponsorNRG Oncology
Enrollment138
ConditionsLocally Recurrent Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8 and Stage III Lung Cancer AJCC v8
DrugsSystemic Chemotherapy
Start18 Dec 2026
Primary completion30 Sept 2029
Study completion30 Sept 2034
Last update posted23 Sept 2026

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase II trial compares repeat radiation therapy (RT) to standard drug treatment alone in treating patients with stage II-III non-small cell lung cancer (NSCLC) that has come back after initial radiation at or adjacent to the site of the original tumor (locally recurrent). Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Chemotherapy drugs used in standard drug treatment work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy drugs used in standard drug treatment may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Targeted therapy drugs used in standard treatment identify and attack specific tumor cells. This trial may help doctors determine whether repeat RT delays the cancer from growing or spreading by 6 months or more after initial radiation compared to standard drug treatment alone in patients with stage II-III locally recurrent NSCLC.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

No facility list is in our current data snapshot for this study. The registry record on ClinicalTrials.gov ↗ carries any published locations. Why? →

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Systemic Chemotherapy
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT07835789

Each answer restates registry values shown on this page.

What is NCT07835789?

NCT07835789 is a phase 2 interventional trial sponsored by NRG Oncology. It studies Systemic Chemotherapy in Locally Recurrent Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8 and 1 more condition.

Is NCT07835789 recruiting?

As of 21 Nov 2026, it is not yet recruiting.

Who leads NCT07835789?

The registry names Nitin Ohri (principal investigator, NRG Oncology) as the overall official.

Which drugs does NCT07835789 study?

The registered drug and biological interventions are Systemic Chemotherapy.

When is NCT07835789 expected to complete?

The registry lists a primary completion date of 30 Sept 2029 and a study completion date of 30 Sept 2034. The sponsor last updated the record on 23 Sept 2026.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.